IRVINE, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced that the company will host an invitation-only, analyst and investor day focusing on two of the company's lead compounds, Eoquin(TM) and ozarelix, on Tuesday, November 28, 2006, beginning at approximately 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time) in New York City.
During the analyst and investor day, presentations will be made by company management and the following experts in the field of urology:
* Fred Witjes, M.D., Ph.D., Chairman of the Urology Group of the EORTC, and Principal Investigator will discuss his experience using Eoquin(TM) as a treatment for non-invasive bladder cancer; * Claus Roehrborn, M.D., Professor and Chairman, UT Southwestern Medical Center at Dallas, Department of Urology, will discuss the prevalence of Benign Prostate Hypertrophy (BPH), the current therapies and limitations with current therapies in treating BPH, and his thoughts on Phase 3 trial design for ozarelix in BPH; * Frans M.J. Debruyne, M.D., Professor and Honorary Chairman, University Medical Center, Nijmegen, the Netherlands, will review ozarelix's mechanism of action, the Phase 2 data of ozarelix in BPH and how ozarelix may improve the current treatment options for BPH; and * Donald Lamm, M.D., Director, BCG Oncology, Phoenix, AZ, and Clinical Professor, University of Arizona, will discuss the current treatment options for bladder cancer in the United States and how Eoquin(TM) would fit into the therapeutic landscape in the United States for treating bladder cancer.
A live audio webcast of the presentation will be available under the investor relations section of Spectrum's website at www.spectrumpharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Spectrum's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals opportunistically acquires and advances a diversified portfolio of drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drug candidates with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at www.spectrumpharm.com.
Forward-looking Statements
This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire and develop its portfolio of drug candidates, the Company's promising pipeline, that ozarelix may improve the current treatment options for BPH and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that past results may not be indicative of future results, the possibility that price and other competitive pressures may make the marketing and sale of our generic drugs not commercially feasible, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of significant revenues, our limited human and financial resources, our limited experience in establishing strategic alliances, our limited marketing experience, our limited experience with the generic drug industry, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
Contacts: Susan Neath Russell Skibsted Porter Novelli Life Sciences SVP & Chief Business Officer (609) 529-0676 Spectrum Pharmaceuticals (650) 678-6155
Spectrum Pharmaceuticals, Inc.CONTACT: Susan Neath of Porter Novelli Life Sciences, +1-609-529-0676, forSpectrum Pharmaceuticals; or Russell Skibsted, SVP & Chief Business Officerof Spectrum Pharmaceuticals, +1-650-678-6155
Web site: http://www.spectrumpharm.com/
